No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
MAGE-A3 is a cancer vaccine developed to target the MAGE-A3 antigen, which is expressed in a variety of tumors. It is designed to stimulate the body's immune system to recognize and attack cancer cells. The MAGE-A3 market is a subset of the larger cancer vaccine market, which is estimated to be worth billions of dollars.
MAGE-A3 is a therapeutic cancer vaccine, meaning it is used to treat existing cancer rather than prevent it. It is used to treat melanoma, non-small cell lung cancer, and bladder cancer. It is administered as an injection and is typically used in combination with other treatments such as chemotherapy or radiation.
The MAGE-A3 market is highly competitive, with several companies developing and marketing their own versions of the vaccine. These companies include GlaxoSmithKline, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more
